To date, only two dual PPARα/γ dual agonists, lobeglitazone and saroglitazar, with predominant PPARα and moderate PPARγ activity with desired potency for the balance of PPARα vs PPARγ activations, have successfully applied in the clinical treatment of T2DM with dyslipidemia, which showed better efficacy and toxicity than TZDs as anti-diabetic drugs (Hong et al., 2018). This evidence concerns the gene PPARA and metabolic syndrome.